Ucwaningo Olusha Lwe-J&J Booster: Isebenza Ngama-85% Ngokumelene Nokulaliswa Esibhedlela I-COVID-19

A BAMBA MahhalaRelease 6 | eTurboNews | eTN
Isithombe sikaLinda Hohnholz
Ibhalwe ngu Linda Hohnholz

Ukuhlaziywa okuhlukile kubonise ukuthi i-Johnson & Johnson COVID-19 i-booster yokugomela ikhiqize ukwanda okuphindwe ka-41 kumasosha omzimba angathathi hlangothi kanye nokwanda okuphindwe ka-5 kwama-T-cell ngokumelene ne-Omicron.

UJohnson & Johnson namuhla bamemezele imiphumela emisha yokuqala yocwaningo lweSisonke lwaseNingizimu Afrika lweSigaba 3b olubonise ukuthi i-booster shot yomuthi wokugomela i-Johnson & Johnson COVID-19 (Ad26.COV2.S) ukhombise ukusebenza kahle okungamaphesenti angama-85 ku-COVID- Ukulaliswa esibhedlela okuhlobene ne-19. Ucwaningo, olwenziwa yiSouth African Medical Research Council (SAMRC), luveze ukuthi i-Johnson & Johnson booster inciphise ubungozi bokulaliswa esibhedlela ngenxa ye-COVID-19 kubasebenzi bezempilo eNingizimu Afrika ngemuva kokuthi u-Omicron ephenduke isidlaliso. Phakathi nezinyanga okufundwa ngazo (maphakathi no-November kuya maphakathi no-December) imvamisa ye-Omicron inyuke isuka kumaphesenti angama-82 yaya kumaphesenti angama-98 abantu abake bathole i-COVID-19 eNingizimu Afrika njengoba kubikwe i-GISAID, isinyathelo esihlinzeka ngedatha ye-COVID-19.     

Ukuhlaziywa kwesibili, okuhlukene kokuphendula kwamasosha omzimba emithini yokugoma ehlukene, okwenziwa yiBeth Israel Deaconess Medical Center (BIDMC), kukhombise ukuthi i-heterologous booster (umuthi wokugoma ohlukile) womgomo kaJohnson & Johnson COVID-19 kubantu abaqale bathola i-BNT162b2. Umuthi wokugomela i-mRNA ukhiqize ukwanda okuphindwe ka-41 ekuphenduleni kwe-antibody kanye nokwanda okuphindwe ka-5 kuma-CD8+ T-cell ku-Omicron ngamaviki amane kulandela ukukhushulwa. Ukukhula okulinganayo nge-BNT162b2 kukhiqize ukwanda okuphindwe ka-17 kumasosha omzimba anciphisa amandla kanye nokwanda okuphindwe ka-1.4 kumaseli e-CD8+ T ngamaviki amane kulandela ukukhushulwa. Kokubili amasosha omzimba anciphisa amandla kanye namaseli e-CD8+ T-cell abephezulu emasontweni amane ngemva kokukhushulwa ngomuthi wokugoma u-Johnson & Johnson kunomgomo we-BNT162b2.

Ukwanda kwamaseli e-CD8+ T-cell akhiqizwe umgomo ka-Johnson & Johnson kungase kube ukhiye ekuchazeni amazinga aphezulu okusebenza ngempumelelo ngokumelene nesifo esinzima se-COVID-19 kanye nokulaliswa esibhedlela ocwaningweni lwe-Sisonke 2, njengoba okuhlukile kwe-Omicron kuboniswe ukuthi kubalekela amasosha omzimba abangela amandla.

Idatha ihanjiswe kuseva yokuphrinta ngaphambilini i-medRxiv ngababhali bezifundo, kulindelwe ukushicilelwa kumajenali abuyekezwe ngontanga.

Isigaba 3b Sisonke 2 Ucwaningo Lokulekelela Ezisebenzini Zokunakekelwa Kwezempilo eNingizimu Afrika

Idatha evela ocwaningweni lwe-Sisonke 2 (n=227,310), olwenziwa phakathi kwabasebenzi bezempilo eNingizimu Afrika abathole umgomo we-Johnson & Johnson COVID-19 oyisibhamu esisodwa njengedosi eyinhloko, ikhombisa ukuthi i-Johnson & Johnson COVID-19 booster inyuse ukusebenza komgomo. (VE) ngokumelene nokulaliswa esibhedlela kumaphesenti angama-85. Lapho kuthathwa i-booster shot ezinyangeni eziyisithupha kuya kweziyisishiyagalolunye ngemuva komthamo owodwa oyinhloko, i-VE yenyuke ngokuhamba kwesikhathi isuka kumaphesenti angama-63 (95% CI, 31-81%) ngezinsuku eziyi-0-13, yaya kumaphesenti angama-84 (95% CI, 67-92). %) ngezinsuku eziyi-14-27 kanye namaphesenti angama-85 (95% CI, 54-95%) ezinyangeni ezi-1-2 zokukhulisa.

ISisonke 2 yenziwa ezikhungweni zokugoma ezibalelwa ku-350 kuzo zonke izifundazwe eziyisishiyagalolunye zaseNingizimu Afrika. Besebenzisa idatha evela ku-Discovery Health, inhlangano yokunakekela ephethwe yaseNingizimu Afrika, abaphenyi bocwaningo bathole i-VE ye-Johnson & Johnson COVID-19 booster shot (n=69,092) uma kuqhathaniswa nabanye abantu ababhalise enhlanganweni efanayo yokunakekela ephethwe, phakathi nenkathi kusukela ngoNovemba. 15, 2021, kuze kube nguDisemba 20, 2021.

Ukubhaliswa kwengalo ye-Sisonke 2 yocwaningo kwaqala ngaphambi nje kokuqala kwegagasi le-Omicron eNingizimu Afrika, okuvumela abacwaningi ukuthi bahlole ukusebenza komgomo weNkampani wokugomela i-COVID-19 ikakhulukazi njengoba i-Omicron yaba uhlobo oluvelele ezweni. Ukucaciswa kwe-genomic kokuhlukaniswa namacala e-COVID-19 akuzange kwenziwe kuleli cala.

Abasebenzi bezempilo basengcupheni eyengeziwe yokutheleleka nge-COVID-19, futhi emazweni anjengeNingizimu Afrika, anabantu abaningi abaphila nezifo ezithathelwanayo, imithelela yokutheleleka kwe-SARS-CoV-2 kubasebenzi bezokunakekelwa kwempilo ijulile kakhulu. Iningi labasebenzi bezokunakekelwa kwempilo baseNingizimu Afrika abashone ngenxa ye-COVID-19 okungenani babe ne-commorbidity eyodwa, futhi abaningi babenezifo eziningi zokugula.

I-Antibody kanye Nezimpendulo ze-T-Cell Ngemva Kwe-Heterologous Boosting Regimen Enkulu kune-After Homologous Regimen Against Omicron Variant

Ukuhlaziywa kwabantu abangu-65 abathole ukugoma okuyisisekelo ngemithamo emibili yomgomo we-mRNA COVID-19 (BNT162b2), kulandelwa i-homologous booster shot ye-BNT162b2 (n=24) noma i-booster ye-heterologous enomgomo we-Johnson & Johnson COVID-19 ( n=41) ngemva okungenani kwezinyanga eziyisithupha, kutholwe zombili izinhlobo zemithi zandise izimpendulo ze-humoral kanye namaselula ngokumelene ne-Omicron.

Izimpendulo ze-antibody ezimelene no-Omicron zikhuthazwe yiwo womabili umgomo wokugomela i-Johnson & Johnson COVID-19 kanye nomuthi wokugomela i-BNT162b2, ngomgomo kaJohnson & Johnson COVID-19 okhuphule ama-antibody titers angasebenzi ngokuphindwe ka-41 emasontweni amane ngemva kokuthuthukiswa. Umuthi wokugomela i-BNT162b2 utholwe ukhuphula ama-antibody titers ezingeni eliphakeme ngeviki lesibili lokuthuthukisa, ngaphambi kokuthi wenqabe ukumela ukwanda okuphindwe ka-17 ngeviki le-post-boost ezine. Ukwanda okuqhubekayo kwamasosha omzimba emasontweni alandela ukugonywa kwe-booster ka-Johnson & Johnson kufana nalokho okubonwa ngemva komgomo wokuqala. Ukusabela okusheshayo kokuzivikela komzimba okulandelwa ukuncipha kokusabela kwe-antibody ngemva kwe-booster ye-BNT162b2 nakho kuyafana nalokho okubonwa ngemva kohlobo lokuqala lwemithamo emibili.

Umuthi wokugomela i-Johnson & Johnson COVID-19 ukhulise ama-CD8+ T-cell amaphakathi ngo-5.5-fold, nama-Omicron-reactive CD4+ T-cells ngo-3.1-fold, kuyilapho uhlobo lwe-homologous (BNT162b2) lukhulise kokubili i-Omicron-reactive CD4+ ne-CD8+ T-cells ngo-1.4-fold.

Ama-T-cell angakhomba futhi abhubhise amaseli angenwe yileli gciwane elibangela i-COVID-19 futhi kukholakala ukuthi aneqhaza ekuvikelekeni ezifweni ezinzima. Ngokuqondile, ama-CD8+ T-cell angabhubhisa amaseli angenwe yileli gciwane futhi asizwa ama-CD4+ T-cell.

Le datha iphakamisa ukuthi ukukhuliswa kwe-heterologous kunamandla okwenza ukuzivikela okuqinile kwe-cell-mediated, okubalulekile kwinkumbulo yokuzivikela komzimba nokuvikela ezifweni ezinzima zepheshana lokuphefumula eliphansi. Ukuqina kwemithi yokuqinisa i-heterologous kanye ne-homologous yokuhluka kwe-SARS-CoV-2 Omicron kusazonqunywa.

Ulwazi Olwengeziwe

Umuthi wokugomela i-Johnson & Johnson COVID-19 ugunyazwe njenge-booster ngabaqondisi abaningi nezinhlangano zokunakekelwa kwezempilo emhlabeni jikelele. U-Johnson & Johnson uyaqhubeka nokuthumela idatha efanele kwabanye abalawuli, i-World Health Organization (WHO) kanye nama-National Immunisation Technical Advisory Groups (NITAGs) emhlabeni wonke ukuze bazise ukuthathwa kwezinqumo ngamasu okuphatha umgomo wendawo, njengoba kudingeka.

Mhla ziyi-16 kuZibandlela wezi-2021, i-US Centers for Disease Control and Prevention (CDC) yagunyaza izincomo ezibuyekeziwe ezenziwe yiKomidi Lokweluleka Lemikhuba Yokugoma (ACIP) zokuvimbela i-COVID-19, izwakalisa ukukhetha komtholampilo kokuthi abantu bathole i-mRNA COVID. -19 umuthi wokugomela i-Johnson & Johnsons COVID-19. E-US, abantu abangakwazi noma abangazimisele ukuthola umgomo we-mRNA bazoqhubeka nokufinyelela kumgomo wokugomela i-Johnson & Johnson COVID-19.

Umuthi wokugoma i-Johnson & Johnson COVID-19 uyinketho ebalulekile yabantu abangakwazi noma abangeke babuye ukuze bayothola imigomo eminingi noma abazohlala bengagonyiwe ngaphandle kwenye indlela yokugomela i-mRNA. Umuthi wokugomela i-Johnson & Johnson COVID-19 uhambisana nezincomo ze-World Health Organization (WHO) zokungenelela kwezokwelapha esimweni esiwubhubhane, ogcizelela kalula ukusatshalaliswa, ukuphatha, nokuhambisana.

Mayelana umbhali

Isithombe sikaLinda Hohnholz

Linda Hohnholz

Umhleli omkhulu we eTurboNews ezinze eTN HQ.

Bhalisa
Yazisa ngakho
isivakashi
0 Amazwana
Okungaphakathi Okuphakelayo
Buka wonke amazwana
0
Ungathanda imibono yakho, ngicela uphawule.x
Yabelana ku...